Message from the President.

Port payé
Poste-Publications
CENTRAL
C A N A DA
CHAPTER
MAY 2000
Postage paid
Publications mail
1551043
8000, Decarie Blvd, 3rd floor
Montreal (Quebec) H4P 2S4
Tel.: (514) 735-5651 Fax: (514) 737-7988
QUARTERLY NEWSLETTER
No.19
Message from the President.
With our year well under way there are a few things we need to acknowledge and review.
I hope to see you all at our next event. Until next time.
Notre année est bien avancée, et nous devons maintenant souligner
certaines activités et évènements.
D’abord, J’aimerais féliciter les membres du conseil Zawdu Eshetu
et Claude Martineau pour leurs efforts couronnés de succès avec
l’établissement de deux chapitres étudiants. Le Chapitre Canada Central a
maintenant un chapitre étudiant avec l’École Polytechnique de Montréal et
l’université Ryerson Polytechnic à Toronto. Les membres étudiants sont
les bienvenus à tous les évènements et séminaires. Joignez-vous à moi
pour les rencontrer et apprendre à les connaître lors de rencontres futures,
et à leur souhaiter la bienvenue comme membres de l’ISPE.
Ensuite, n’oublions pas l’évènement social de l’année, le 7ème tournoi
annuel de golf du Chapitre Canada Central. Cette année, le tournoi sera
tenu au "Richmond Hill Golf Club" à Richmond Hill, Ont. Des invitations
ont été envoyées aux fournisseurs et je remercie ceux qui ont déjà répondu
pour leur participation à cet événement. Tout fournisseur intéressé à
participer qui n’aurait pas reçu son invitation devrait me contacter aussitôt
que possible. Si vous n’êtes pas un membre fournisseur et que vous
vouliez jouer, contactez au plus vite votre fournisseur préféré pour réserver
votre place dans l’équipe ou l’ISPE pour jouer à titre personnel. Comme
d’habitude, tout don pour des prix de présence serait apprécié.
Nous avons eu plusieurs séminaires intéressants cette année. Nous allons
maintenant prendre un repos mérité durant la période estivale. Alors que
plusieurs séminaires ont connu un grand succès, le conseil d’administration
est déçu de la participation générale des membres. Il est important
d’obtenir une meilleure participation pour obtenir la participation de
conférenciers de premier plan. Afin de connaître les goûts des membres,
nous vous envoyons un questionnaire (par courriel) qui nous aidera à
coordonner les meilleurs programmes pour l’année à venir. Si vous n’avez
pas reçu ce questionnaire, veuillez me contacter.
Finalement, la plupart de nos conférenciers viennent de compagnies
fournissant des produits ou service à l’industrie. Nous avons maintenant
besoin des conférenciers provenant de l’industrie. La somme de connaissances d es membres pro venant de l’industrie e st in égalée.
Historiquement, ces conférenciers ont aussi attiré les plus grandes participations. Je vous encourage à nous contacter et à partager vos expériences
avec vos collègues. Nous avons besoin de votre aide pour fournie les
meilleurs programmes éducatifs possibles.
Perry F. Elliot, President
J’espère vous rencontrer à notre prochain évènement, à la prochaine!
First, my congratulations to Board Members Zawdu Eshetu and Claude
Martineau for their successful efforts in establishing two Student Chapters.
The Central Canada Chapter now has Student Chapters located at Ecole
Polytechnique in Montreal and Ryerson Polytechnic University in Toronto.
Student members are welcome at all Chapter Events and Seminars so
please take the time to get to know them and join me in welcoming them
to the ISPE.
Second, let us not forget the social highlight of the year, the 7th Annual
ISPE Central Canada Chapter Golf Tournament. This year, the tournament
will once again be held at the Richmond Hill Golf Club in Richmond Hill,
ON. Invitations have been sent to the Vendors and I thank those that have
already responded for their support of this event. Any interested Vendors
that have not received an invitation should contact me without delay. If
you are not a Vendor and you want to play, now is the time to contact your
favourite Vendor to reserve your place on their team. As always, any donations for the prize table will be greatly appreciated.
Third, we have had several very interesting seminars so far this year. Now
we will take a break until the fall. Although some of the seminars were
well attended, for the most part the Board is disappointed with the overall
attendance levels. It is imperative that we increase attendance levels to
attract the best speakers. In order to ensure that the Chapter is meeting
the requirements of the membership we are sending a survey to all members via e-mail. If you do not receive one please contact me. The results
of this survey will assist us in coordinating the most interesting programs for
you, our members. Hopefully, this will result in larger turnouts for our events.
Fourth, it is not usually difficult for us to attract speakers from Vendor companies, however, we have not been very successful getting representatives
from end-user companies to present at our seminars. The pool of knowledge and expertise that is available from this sector of our industry is
unparalleled. Historically, these speakers have also drawn the largest
crowds. I encourage any interested parties to come forward to share your
experiences with your colleagues. We need your help to provide the best
educational programs we can.
Perry F. Elliot, Président
IN THIS ISSUE
Members of the Board
7th Annual ISPE Golf Tournament
ISPE Welcomes Ryerson Polytechnic University
Chapitre étudiant ISPE de l’école Polytechnique
• Présentation des premiers membres étudiants
Packaging debunking some myths
ISPE Breakfast Seminar
p.2
p.3
p.4
p.4
p.5
p.6
p.7
How is Our Air Cleaned?
Security is more than just a firewall...
World Pharmaceuticals News
Pharmaceuticals Engineering
Third Party Logistics
Internet: Find what you’re looking for Faster!
Upcoming ISPE events
1
p.8
p.9
p.10
p.13
p.14
p.15
p.16
MAY 2000
CENTRAL CANADA CHAPTER
No.19
Members of the Board
Perry Elliot
Healthstar Limited
PRESIDENT
Golf Tournamant Committee Chair
Vendors Coordinator
TEL. 905-791-7735
FAX. 905-791-7736
Mobile: 416-460-7498
[email protected]
Zawdu Eshetu
Novopharm Limited
VICE-PRESIDENT
Toronto Student Chapter Chair
T E L . 416-291-8888, ext. 5170
FAX. 416-291-6124
[email protected]
Steve Mons
DT Kalish
SECRETARY
Vendors Committee Chair
T E L . 514-694-2390, ext. 224
FAX. 514-694-6552
[email protected]
Daniel Lachapelle
Pellemon Inc.
TREASURER
Montreal Student Council Chair
TEL. 514-735-5651
FAX. 514-737-7988
[email protected]
Ro b e rt Gagnon
Novopharm Limited
PAST-PRESIDENT
Government Affairs Committee Chair
T E L . 416-291-8888, ext. 5332
FAX. 416-291-0260
[email protected]
André-Pierre Ghys
Pellemon Inc.
DIRECTOR
AGM Committee Chair
Website Committee Chair
TEL. 514-735-5651
FAX. 514-737-7988
[email protected]
Ben Roczniak
Biolab
DIRECTOR
TEL. 514-636-0032
FAX. 514-636-8429
[email protected]
Membership Committee Chair
AGM Coordinator
Genpharm Inc.
Publications Committee Chair
TEL. 416-207-1229
FAX. 416-236-3675
[email protected]
Geoff Pilmoor
AstraZeneca Inc.
DIRECTOR
TEL. 905-615-6876
FAX. 905-275-0706
[email protected]
Mark Butte r w o rt h
G l a x o Wellcome Inc.
DIRECTOR
TEL. 905-819-3254
FAX. 905-819-3442
[email protected]
Claude Mart i n e a u
ICN Canada
DIRECTOR
T E L . 514-744-6798 ext. 2294
FAX. 514-744-6238
[email protected]
AGM Coordinator
• ISPE Central Canada
www.ispec-canada.org
• ISPE Headquarters
www.ispe.org
SONDAGE
Tirage de 150$
Le chapitre du Centre du Canada a préparé un
sondage dans le but d’offrir des activités qui
répondent davantage aux besoins de ses
membres.
Par conséquent, nous vous invitons à répondre
au questionnaire et à le retourner avant le
16 juin 2000.
Tous l es m embres qu i ré po ndro nt à ce
questionnaire se verront la chance de gagner
un prix de 150 $ pour aller manger dans le
restaurant de leur choix. Le tirage aura lieu
vendredi le 23 juin 2000 lors du tournoi
de golf annuel de ISPE (si la personne gagnante du tirage n’est pas au tournoi de golf,
elle sera avisée dans les jours suivants).
Répondez en grand nombre, vos réponses, vos
propositions et vos commentaires seront lus et
pris en considération.
Ingénieur de projets, Production et Maintenance
ICN Canada
DIRECTOR
Education Committee Chair
Websites
Claude Martineau, ing., M. ing., M.B.A.
Rogelio Abarca
Management Services Committee Chair
Golf Tournamant Coordinator
ISPE
2
[email protected]
tél. (514) 744-6798 poste 2294
fax (514) 744-6272
1956, rue Bourdon
Ville St-Laurent (Québec) H4M 1V1
Please help us keep our records current. If
you have moved or if your numbers have
changed, please send a brief e-mail to
[email protected].
* Th e opi ni ons expr esse d are tho se o f th e
authors of the articles, and do not necessarily
reflect the views of ISPE, the Central Canada
Chapter, or their Boards of Directors.
CENTRAL CANADA CHAPTER
MAY 2000
No.19
INVITATION
7th Annual ISPE Golf Tournament
June 23, 2000 Toronto
Invitation to Vendors-Sponsors:
This is your chance to fax in your registrations as the sponsors of one or more foursomes at our 2000 Golf
Tournament next June 23, 2000. The tournament will be held at the Richmond Hill Golf Club in Richmond Hill,
Ontario. It will be a scramble format and we will have a shotgun start at 12:00 pm sharp.
Individual Golfer Registration:
For those who wish to attend as individual golfers, they can either register as such and be randomly assigned a
foursome, or attempt to regroup with others in the same situation, in order to form a full foursome.
Vendor (s) Reps Limit:
We remind all that our previous rules of a max. of 2 vendor(s) reps per foursome is still our goal.
HOLE SPONSORSHIP:
A sign with your company name can be placed at a hole and at the prize table, recognizing your special sponsorship, for a fee
of $ 500.00 . Also, you can sponsor any of the contests (closet to the pin, hole in one, longest drive, putting contest etc.).
Please call Perry Elliot at (905) 791-7735 for more information.
Registration Slip
Foursome Sponsors
Fee per foursome (Golf & Dinner)
Name:
Company:
Phone: ( )
E-mail:
ISPE member
ISPE Non-member
$ 500.00
$ 600.00
Fax: ( )
Individual Registration
Fee per foursome (Golf & Dinner)
Name:
Company:
Phone: ( )
E-mail:
ISPE member
ISPE Non-member
$ 125.00
$ 150.00
Fax: ( )
Please return this registration form by fax to Perry Elliot @ (905) 791-7736 by June 2nd, 2000. Payment must be received by June 9, 2000..
Cheque should be sent to ISPE Central Canada, 8000 boul. Décarie, bureau 300, Montréal, Québec H4P 2S4. Please make cheques payable
to ISPE Central Canada.
Yours very truly,
Perry Elliot, President
ISPE Central Canada
3
MAY 2000
CENTRAL CANADA CHAPTER
No.19
ISPE
Welcomes Ryerson Polytechnic University!
Ryerson Polytechnic University (RPU) is the first university in Ontario and the second in Canada to have joined the International Society of
Pharmaceutical Engineering (ISPE).
The idea of ISPE student chapter at RPU was inspired by the presentation of Mr. Perry Elliot and Mr. Zawdu Eshetu, respectively the president and vice
president of ISPE Central Canada Chapter, on March 2, 2000. This presentation was made possible with the co-operation of Mark Wasilewski (3rd year
Chemical Engineering student) and Dr. R. Dhib (Professor of Chemical Engineering) at RPU.
Over 50 students and 10 staffs from the Department of Biology, Chemistry and Chemical Engineering of Ryerson Polytechnic University attended this
ISPE presentation. At the end of presentation, a group of enthusiast students showed their interest in forming a student chapter at Ryerson Polytechnic
University. Seeing the great interest of student in ISPE, the vice-president of ISPE Canada Central, Mr. Zawdu Eshetu, made an appointment with them for
the following week.
On March 9,2000 the ISPE student chapter of RPU was born. Presently, this chapter has a dozen members. The board members were nominated and
elected by the students in presence of Mr. Zawdu Eshetu (ISPE/Industry advisor) and Dr. Rahmdan Dhib (Faculty advisor). The following is a list of the
officers, board members and how they can be contacted:
Mark Wasilewski, President
(416) 533 - 6678
[email protected]
Mesrak Lissanu, Vice-president
(416) 944-2903
[email protected]
Jessica Perryman, Secretary
(416) 742-9001
[email protected]
Shernell Layne, Treasurer
(416) 247-8004
[email protected]
Dalia Gendy, Member at Large
(905) 608-1160
[email protected]
Industry/ISPE and Facility Advisors:
Zawdu Eshetu, ISPE Advisor
Dr. Ramhadne Dhib, Faculty Advisor
(416) 291-8888 ext-5170
(416) 979 5000 ext-6343
The goal and objective of ISPE student chapter of RPU is to inform students about the Pharmaceuticals Industry, have plant tours, attend ISPE breakfast
seminar, have guest speakers at RPU and get familiar with the vocabulary of this vast industry. The majority of the members of this student chapter are
planning to build a career in the pharmaceutical industry.
To achieve their goals and dreams, the ISPE student chapter at RPU needs the help, time and co-operation of professionals in this field. This student
chapter is requesting the support and guidance of members of ISPE Canada Central. The board members and all other members of ISPE student chapter
of Ryerson Polytechnic University are eager to hear from members of ISPE Central Canada in the near future.
Durkhani Hadia Kakar, Member, ISPE Ryerson Polytechnic Student Chapter
Chapitre étudiant de
ISPE
de l’école Polytechnique
Les quatre derniers mois ont été fort occupés pour moi . J’ai pris la
responsabilité de démarrer un chapitre étudiant de ISPE à l’École
Polytechnique.
tirage d’une paire de billets de hockey gracieuseté de Pellemon, afin
d’amasser des fonds pour organiser des activités.
Le 20 avril, ils ont été visité la compagnie Wyeth Ayerst ce qui fut leur
troisième activité.
Les buts visés quant au démarrage d’un chapitre étudiant de ISPE sont
de développer une relève dynamique pour l’industrie pharmaceutique et
aussi de permettre à des étudiants de se développer un réseau de contacts
dans notre industrie.
Finalement le 2 mai, ils ont tenu leur troisième réunion. Ils ont alors
discuté des trois activités qu’ils avaient réalisées au cours des deux derniers
mois et ils ont débuté la planification pour le recrutement de nouveaux
membres lors de l’entrée scolaire de septembre 2000.
Par conséquent, le 28 janvier dernier, j’ai été rencontré les étudiants de
l’École Polytechnique et je leur ai présenté ISPE et les avantages d’être
membre-étudiant de ISPE. Dans les semaines suivantes, sept étudiants
ont complété leur formulaire d’adhésion. Par la suite, trois autres étudiants
se sont ajoutés pour un total de 10 membres-étudiants.
Dans les prochaines lignes, vous trouverez des articles faits par ces
membres étudiants où ils se présenteront et aussi parleront des activités
qu’ils ont organisés.
Pour terminer, je travaille à démarrer d’autres nouveaux chapitres-étudiants
de ISPE et j’espère que ça ira aussi bien qu’à l’École Polytechnique.
Le 25 février, les étudiants ont fait leur première réunion où ils ont élu
leur conseil d’administration et planifié les activités qu’ils organiseraient
dans les prochains mois dont une conférence et une visite industrielle.
S’il y a des membres qui sont intéressés à s’impliquer pour donner des
conférences, organiser une visite de leur usine, pour donner un stage aux
membres étudiants de ISPE, etc. je vous invite à communiquer avec moi
ou bien avec les membres du conseil d’administration du chapitre du
Centre du Canada.
Le 10 mars, ils ont tenu leur deuxième réunion afin de voir à l’organisation de la conférence et à la planification de la visite industrielle.
Le 17 mars, leur première activité soit une conférence donné par Mark
Cupryk de Merck Frosst et André-Pierre Ghys de chez Pellemon a eu lieu à
l’École Polytechnique.
Claude Martineau, ing., M. ing., M.B.A.
Ingénieur de projets, Production et Maintenance, ICN Canada
Du 20 mars au 3 avril, ils ont organisé leur deuxième activité soit un
4
JANUARY 1999
CENTRAL CANADA CHAPTER
No.19
Chapitre étudiant de
ISPE
de l’école Polytechnique
Présentation des premiers membres étudiants
Bonjour à tous,
Je m’appelle Sébastien Sarrailh, je suis un étudiant de 3e année en
génie chimique (orientation génie pharmaceutique) et je vais bientôt
réaliser un stage de huit mois dans une entreprise pharmaceutique
appelée Laboratoires Confab. Je suis très content de vous annoncer qu’un
premier chapitre étudiant de l’ISPE du centre du Canada vient d’être fondé
à l’École Polytechnique. En tant que président de ce tout nouveau
chapitre, mon principal objectif est de faire connaître l’ISPE et le génie
pharmaceutique à l’École Polytechnique. Pour ce faire, j’ai l’intention d’organiser plusieurs activités telles des midi-conférences, des visites industrielles et des campagnes de financement et recrutement afin de susciter
l’intérêt du plus d’étudiants possible à l’industrie pharmaceutique. J’ai
pleine confiance que tous ces projets seront accomplis avec succès car je
suis épaulé par une excellente équipe d’étudiants dont j’ai pour la plupart
déjà observé leurs grandes compétences lors de divers travaux d’équipes
dans différents cours de génie chimique à l’École Polytechnique. À ce jour,
le chapitre étudiant de l’ISPE à l’École Polytechnique est constitué de neuf
membres, les voici en commençant par le comité exécutif : Marie-Esther
Biron (vice-présidente), Mathieu Leduc (secrétaire), Dimitrios Saponas
(trésorier), Annie Sénéchal (directrice des activités), Dora Gmati,
Jean-Philippe Gingras, Philippe Lessard, David Brown.
Bonjour,
Étant présentement étudiante en génie chimique (option pharmaceutique), j’ai trouvé l’idée de former un chapitre étudiant canadien de l’ISPE
fort intéressante. En effet, être membre de l’ISPE me permettra d’élargir
mon champ de connaissances et d’établir des contacts dans le domaine
pharmaceutique.
En plus d’être membre de l’ISPE, je participe à l’organisation des activités du chapitre étudiant. Ainsi, j’aimerais planifier des dîners-conférences
dont les sujets traiteraient de plusieurs aspects tels que le domaine pharmaceutique, la validation, les biotechnologies… De plus, il serait intéressant d’organiser des visites industrielles afin de mieux connaître les entreprises pharmaceutiques et de réaliser concrètement le rôle de l’ingénieur
dans ce milieu. Enfin, j’aimerais aussi planifier d’autres petites activités, un
kiosque d’information par exemple, qui permettrait de faire connaître cette
spécialité du génie ainsi que l’ISPE aux autres étudiants de l’École
Polytechnique de Montréal.
Annie Sénéchal
Directrice des activités du chapitre étudiant de l’ISPE à l’École Polytechnique
Je m’appelle Jean-Philippe Gingras et je suis un étudiant de troisième
année en Génie Chimique ayant choisi la toute nouvelle orientation en
Génie Pharmaceutique. C’est évidemment pour cette raison que j’ai été
poussé à devenir membre de l’ISPE et du même coup, participer à la fondation d’un chapitre étudiant. Cette organisation m’intéresse d'autant plus
qu'elle permettra de me donner une vision d’ensemble de l’industrie pharmaceutique. Ainsi, contrairement au cours où la matière nous est le plus
souvent imposée, le chapitre étudiant de l'ISPE pourra nous permettre de
nous familiariser avec le milieu selon nos propres intérêts et dans un contexte plus détendu.
Sébastien Sarrailh
Président du chapitre étudiant de l’ISPE à l’École Polytechnique
[email protected]
Je suis étudiante en génie chimique orientation pharmaceutique depuis
le début de la session automne 1999. Suite à la réalisation d’un stage de
huit mois dans le milieu pharmaceutique, je manifeste maintenant le désir
de poursuivre une carrière dans ce domaine, d’où l’intérêt de m’impliquer
aujourd’hui dans le chapitre étudiant de l’ISPE. Ma dernière année au baccalauréat à l’école Polytechnique de Montréal est présentement entamée
et je terminerai mes études en décembre 2000.
En tant que Vice-Présidente du chapitre étudiant de l’ISPE, je compte
tout d’abord apporter le support nécessaire au président dans l’accomplissement de ses tâches et l’appui nécessaire aux autres membres du
comité à la réalisation d’activités telles que des visites industrielles, conférences, etc., ainsi qu’au recrutement de nouveaux membres. En l’absence du président, j’assumerai les responsabilités de ce dernier et veillerai
au un bon déroulement des activités. Enfin, je serai aussi prête à assumer
les responsabilités qui me seront confiées par le Président.
Jean-Philippe Gingras
Membre du chapitre étudiant de l’ISPE à l’École Polytechnique
Les étudiants et les conseillers
Marie-Esther Biron
Vice-présidente du chapitre étudiant de l’ISPE à l’École Polytechnique
Je m’appelle Mathieu Leduc et je suis le premier secrétaire de la première branche étudiante de l’ISPE au Canada. Je suis très fier de faire parti
de cette organisation prestigieuse. Je suis un étudiant de 3e année à l’école Polytechnique de Montréal en génie pharmaceutique. Outre l’école,
j’adore m’adonner à plusieurs sports tel que le hockey, le golf et la ballemolle. Mon objectif en tant que secrétaire est d’appuyer à fond notre
valeureux président (Sébastien Sarrailh), et de rendre compte du contenu
des réunions à tous nos membres assidus. La réussite de ces objectifs me
tient vraiment à cœur et je ferai tout mon possible pour assurer la réussite
de ce projet.
1ère rangée : Dora Gmati (membre), Annie Sénéchal (directrice des activivés),
Marie-Esther Biron (vice-présidente), David Brown (membre).
2e rangée : Claude Martineau (représentant du Cental Canada Board of ISPE),
Dimitrios Saponas (trésorier), Mathieu Leduc (secrétaire), Philippe Lessard
(membre), Sébastien Sarrailh (président), Jean-Philippe Gingras (membre),
Mario Jolicoeur (professeur à Polytechnique et aussi membre de ISPE).
Mathieu Leduc
Secrétaire du chapitre étudiant de l’ISPE à l’École Polytechnique
5
CENTRAL CANADA CHAPTER
MAY 2000
No.19
Campagne de financement du Chapitre étudiant ISPE
de l’école Polytechnique de Montréal
La première campagne de financement du Chapitre Étudiant ISPE de l’École
Polytechnique a pris la forme d’un tirage d’une paire de billets de prestige
pour une partie des Canadiens au Centre Molson, grâce à un don généreux
de Pellemon.
La vente de billets de tirage à 2$ s’est déroulée du 17 mars au 3 avril à
l’École Polytechnique de Montréal, où nous avions érigé un petit kiosque de
vente sur l’heure du midi, et en dehors des heures de cours parmi les nombreuses connaissances de nos populaires membres du Chapitre Étudiant.
Le bilan de cette dynamique campagne de financement apporte donc deux
résultats positifs :
• Un gagnant : Jean-François Sénéchal, étudiant finissant en génie chimique,
dont le nom a été tiré au hasard le Lundi 3 avril à 12h30 lors d’une réunion
officielle du Comité de Génie Chimique à l’École Polytechnique. Celui-ci
aura donc la chance d’assister au match du 6 avril au Centre Molson
entre les Canadiens de Montréal et le Lightning de Tampa Bay dans la
section Air Canada.
• Un Chapitre Étudiant de l’ISPE plus riche de 242$!
En conclusion, l’argent ramassé va être placé dans un compte en banque au
nom du Chapitre Étudiant jusqu’à ce que son utilisation soit déterminée,
sujet à l’ordre du jour de notre prochaine réunion.
En terminant, je veux remercier tous ceux qui ont contribué au succès de
cette première campagne de financement, soit notre généreux commanditaire Pellemon, notre dévoué conseiller ISPE Claude Martineau, tous les
membres du Chapitre Étudiant ISPE et bien sûr, tous ceux qui nous ont
encouragé en participant au tirage.
Sébastien Sarrailh, Président, Chapitre Étudiant ISPE de l’École Polytechnique
Packaging
debunking some myths
Packaging is vital to today’s economy in many ways. Most obviously they allow producers to market and differentiate their product from others.
Packaging facilitates transportation and distribution while most importantly to the pharmaceutical industry communicates essential product information i.e.,
dosage, directions, warnings etc. Folding cartons are the most versatile and widespread type of packaging in use today. Although one of the most established
forms of packaging, they are still innovative, exciting and offer the only packaging solution that is derived from naturally renewable materials – wood fiber.
Few Canadians appreciate how critical forestry is to our economy and
national well being. Forestry still remains our single most important industry. Almost a quarter million Canadians are directly dependent on the
industry, while another three quarters of a million are indirectly dependent.
These numbers represent 1 out of every 12 Canadians working in this
country. Still fewer Canadians realize that our forests are increasing in size
not decreasing as certain vested interests would have us believe. There
are 4.18 million square kilometers of forest in this country, but only
10,000 square kilometers are harvested each year. What is harvested, is
regenerated and 650 million trees are planted annually. That’s 23 trees
for every man, woman and child in this country. The most recent United
Nations study concluded that Canada’s forests have increased in size by
9000 square kilometers from 1990 to 1995.
Carton manufacturing has always been more environmentally friendly
than other materials, especially tin and plastic. The paper industry
reduced its fossil fuel consumption by 20% between 1990 and 1994
and has continued this impressive reduction by shifting more and more to
waste wood and biomass. No ozone-depleting substances are used in
production and over 97% of inks used for printing are water-based and
non-toxic. The industry has completed a $5 billion pollution abatement
program, which has effectively eliminated dioxins in the waste stream of
its facilities.
Canadians should be proud of the major achievements they have
made in packaging waste reduction. Despite an increase of 11% in packaging users we have slashed our packaging trash by over 50%, four years
ahead of target. Impressively, and unlike most European nations, we
achieved this reduction voluntarily without regulation. Approximately 70%
of all paper-based packaging used in Canada is re-used or recycled.
Now back to paperboard packaging – another myth is that the industry
cuts down trees every time it needs to make a paperboard box or carton.
This is not even close to the truth – in fact only 10% of all paper-based
packaging made for Canadians is actually made from freshly cut logs. Over
90% is made from recycled paper and board and/or chips, shavings and
sawdust left over from logging and wood processing operations. As a
result paperboard packaging has by far the highest rate of recycled materials – i.e., four times that for plastic.
Packaging
Manufacturing
Quality Assurance
Engineering
Validation
Canada has continually taken a leadership role in forestry and packaging matters. As consumers, we can be justifiably proud of our collective
efforts when we choose paperboard-packaged goods.
Contributed by J. Clarke
Ellis Packaging Limited
• Complete liquid/tablet packaging lines
• Cartoners/tube fillers, metal detectors and checkweighers
• Blistering and de-blistering equipment
• Tablet compression
• Dissolution/desintegration
• Complete installation/line layouts/Project Management
• Validation Protocols
Montreal
Toronto
New Jersey
Chicago
(514) 694-2390
(905) 542-8080
(908) 685-0888
(847) 229-7222
6
MAY 2000
CENTRAL CANADA CHAPTER
ISPE
Breakfast Seminar
No.19
• Feb 22nd, 2000
Core Competency Model for Pharmaceutical
Project Managers
Conférence sur un modèle de compétences pour les
Presented by Dr. Martin Hynes lll, Director of Pharmaceutical
gestionnaires de projets pharmaceutiques
Project Management, Eli Lilly & Co.
This seminar was very well supported with 105 attendees and this resulted
in a change of venue to the Lionhead Golf & Country Club a couple of kilometers North of the GlaxoWellcome facility in Mississauga.
Dr. Hynes’s presentation was based on a paper that he presented in
Philadelphia at the 30th Annual Project Management Institute Seminars in
October of 1999. Before the establishment of Drug Development Project
Management at Eli Lilly drug development project teams were usually led
by the research scientist who had made the discovery. This was seen as
recognition for research success. The result was that projects were led by
people with little or no project management training or experience. The
project managers’ main function would often be managing a research lab
and project management activities would be fitted into whatever spare
time they could conjure up. Project managers could become so attached
to "their" drug that it was very difficult to terminate projects and decisions
were often made on an emotional rather than data basis. Drug development
projects and teams could meander along their 14 or 15 year life without a
clear, well documented project management process to guide them.
With the need to get more new drugs to market more quickly Eli Lilly’s
senior management initiated a major paradigm shift in drug development
project management in the mid 1980’s.
Technical staff were taken out of the research lab environment to focus on
drug development project management.
To support this initiative by identifying, attracting and retaining the most
competent project managers Eli Lilly developed a Core Competency Model
for Pharmaceutical Project Managers. This was done using bench marking
with other high tech companies and using similar studies done by PMI,
DOD and Fortune 500. There are many similar conclusions throughout the
different studies.
The model identifies 13 core competencies, which are separated into 3
groups; Scientific/Technical, Process (Project Management) and Leadership.
Risk management and communication skills are probably the highest ranking competencies. Dr Hynes proposed that risk is the issue that differentiates drug development projects from projects in other fields. New drug
development projects have cost estimates ranging from $300M to $600M
and a very high rate of attrition.
A competency that probably cannot be learnt is the Project Manager’s character. Dr. Hynes emphasized that drug development project management
is not for the faint of heart!
Eli Lilly allocates 1 to 3 projects to each project manager and may change
project managers and teams at different project phases. A dedicated, more
commercially focussed team may replace an early, cross-functional, discovery
phase program team at the phase 3 clinical trial stage.
The implementation and development of drug development project management has resulted in effective management and control of their projects. The use of the Core Competency Model has established project
management as a discipline at Elli Lilly that can offer a career development
path equivalent to that available in scientific or managerial functions.
Good luck, go and get some results, based on Dr. Hynes’s experiences the
results are worth the effort.
If you didn’t attend this seminar try the next one, you may be surprised
what you learn.
Plus d’une trentaine de personnes ont assisté, au Quality Hotel de
Dorval, au déjeuner-conférence organisé conjointement par le Chapitre
Central Canada de l’International Society for Pharmaceutical Engineering
et le Project Management Institute - Pharmaceutical sur la gestion de
projets pharmaceutiques.
La conférence était présentée par Dr. Martin Hynes III, directeur de projets pharmaceutiques chez Eli Lilly & Co., et traitait principalement de
l’élaboration d’un modèle de compétences pour les gestionnaires de
projets pharmaceutiques.
La gestion de projets pharmaceutiques étant un principe relativement
récent, la mission de Eli Lilly & Co. a été de développer un modèle de
compétences dans le but de retenir les meilleurs gestionnaires, de
développer leur leadership et d’optimiser toutes les phases de
développement et d’incorporation de tout nouveau médicament sur le
marché.
Pour développer le modèle de compétences, Eli Lilly & Co. a utilisé quatre sources d’informations, soit la documentation professionnelle spécifique au sujet, les standards de l’industrie, les données et les résultats
des leaders du domaine. Les gestionnaires internes les plus performants
ont aussi été interrogés par l’intermédiaire d’entrevues. Le modèle
obtenu vise à établir les critères de sélection, de développement et de
promotion du personnel et s’applique tant au personnel technique
qu’aux gestionnaires.
À la suite du travail du groupe, treize compétences pour un gestionnaire
de projets ont été identifiées et réparties en trois catégories pour l’élaboration du modèle de compétences.
La première catégorie, appelée «Scientific/Technical Core Competency»,
représente une catégorie dans laquelle le gestionnaire doit posséder une
bonne connaissance du marché, doit planifier et anticiper les risques des
projets et être proactif.
Un gestionnaire qui communique clairement les informations, porte
attention aux détails, est très structuré avec des objectifs clairs et précis
fait p artie de la d eu xième catégorie, a ppelée «Proces s Core
Competency».
La dernière catégorie, «Leadership Core Competency», représente les
personnes axées sur les résultats, qui développent l’esprit d’équipe et qui
gèrent des situations complexes. Ces personnes sont également capables de prendre des décisions difficiles et d’obtenir l’appui de leurs
supérieurs.
Quelques exemples concrets ont été apportés au cours de la présentation, démontrant ainsi l’impact sur un projet d’un gestionnaire qui possède ou non une des compétences de base susmentionnées.
Le modèle de compétences développé a permis à cette compagnie de
réduire de façon considérable le temps de mise en marché d’un médicament. L’exemple de Eli Lilly & Co. est maintenant devenu une référence
disponible dans un ouvrage publié par John Wiley & Sons sous le titre de
«Applied Project Management : Best Practices on Implementation».
Finalement, la qualité des discussions au cours de la présentation a permis à tous les participants de tirer profit de cette activité, sans oublier
qu’un tel événement permet également de promouvoir l’échange d’informations techniques reliées à l’industrie pharmaceutique.
Merci au conférencier, aux organisateurs et à tous pour votre participation.
Martine Rondeau, ing., Pellemon
Mike Coney
7
MAY 2000
CENTRAL CANADA CHAPTER
No.19
How is Our Air Cleaned?
When it comes to air cleaning, i.e., removing particles from the air, the most basic way of doing so is a mechanical filter. Yet selecting the
type of filter to use can be complicated, as factors such as filter efficiency, dust holding capacity, operating costs and fan capacity must all be
considered to determine which system is best for the job.
average efficiency of 98%. In the ionization section, small diameter wires
create a magnetic field which positively charges the particle in the ductwork. The collecting plates are kept at ground potential and remove the
particulates from the air. These air cleaners require periodic (monthly)
cleaning with detergent and water. They also loose efficiency as they
become dirty, unlike a mechanical filter, and are more difficult to measure
a service interval.
Particles in the atmosphere range in size from .01 mm (tobacco
smoke), to 1mm (bacteria, dust) to 50 mm (human hair) and above.
Traditional furnace filters, known as panel filters, are made of densely
packed glass or synthetic fibers and may contain a coating to act as an
adhesive for particulate matter. These filters collect large particles but
remove only a small percentage of respirable size particles; they would be
considered 20% efficient. Pleated filters are the next step up in performance, see Figure 1. They have a greater surface area so that smaller
fibers can be used without a large drop in flow rate. The deeper the
pleats, the greater the dust holding capacity.
Stefano Spangaro, [email protected]
Diagrammatic Cross Section of Ionizing-Type
Electronic Air Cleaner
HEPA (High Efficiency Particulate Air) filters and now ULPA (Ultra Low
Penetration Air) filters are a class above the standard pleated types, able to
achieve up to 99.9999 efficiency at .1 mm. These are made with a series
of submicron glass fiber paper pleats, usually sealed into a metal housing,
which is in turn gasketed into the ductwork.
Most clean rooms use HEPA filters as the final cleaning station before
the air hits the open product. Pleated filters would be used to take out the
larger particles and extend the life of the more fragile filters. In most cases,
a dirty filter is more efficient: the dust fills the pores and prevents smaller
particles from getting by. A dirty filter is also more difficult to pass air across,
resulting in less total airflow or increased energy in the fan to keep the same
volume. Monitoring the differential pressure across a filter, or the amount
of resistance, is a simple way to determine when it is replacement time.
Figure 2
Figure 1
Electronic air cleaners are a different and highly efficient way to collect
and remove contaminants such as dust, smoke and pollen. The type of air
cleaner, shown in Figure 2 can remove airborne contaminants with an
ASHRAE
Equipment Handbook
1988
WhyDe-Blister?
Q: Why would a company want to remove tablets and capsules from
blister packs?
A: Frequently, during blister packing, the product filler momentarily jams leaving a
pocket empty. The machine detects this and rejects the blister after sealing. By
immediately recovering the good product it can be returned to the hopper and
repackaged into a good blister. 100% SUCCESS
Q: Does that mean that it is possible to take the waste foil and dispose
of it with regular paper trash?
A: Yes, in fact many companies realize vast savings by this application alone. It is
very expensive to pay for incineration or disposal of active product and, of course,
if the filled blister is being incinerated the company is paying high rates for the
incineration of large air spaces and packaging materials unnecessarily.
INDUSTRIAL STANDARD
Q: Why do they not just make sure the feed doesn't jam?
A: It does not make sense to spend time trying to get a full 100% yield from an
expensive blister packer which may be giving 95% yield. It is much simpler and
more sensible to use a separate process (semi or automatic de-blistering) to
achieve that last 5%. REDUCE INVENTORY
Q: What happens if the tablets are different colors or sizes?
A: Certain manufacturers design their machines so that it is possible to separate
the different products and keep them separate.
Q: Is it not cheaper to get staff to press out the blisters by hand?
A: Hand recovery of 50,000 blisters costs about $16,650, in labor costs alone.
The job is painful, can lead to repetitive strain injury and is extremely de-motivating
as well as being a wasteful use of human resources. For situations where it is not
possible to justify a fully automatic machine, there are machines developed that
are hand operated machines. PRODUCT FRIENDLY
Q: Why else would a blister need to be de-packaged?
A: Sometimes rejects are caused by poor print registration, faulty batch number,
wrong expiry date - even the wrong foil has been used. But it is not only for negative reasons that de-blistering is carried out. It is possible to take regular stock of
one blister size, de-blister it, and immediately repack it into small sample blisters.
This gives Marketing much greater flexibility in accessing markets quickly and can
also help to reduce inventory to a minimum.
Q. What if the tablets are soft?
A: So long as the tablets are strong enough to withstand hand de-blistering they
can be de-blistered. The same can be said with capsules.
Q: How can you be sure that the product is not damaged or contaminated?
A: Certain de-blistering machine manufacturers use rollers that are designed very
accurately so that the tablets pass exactly between the gaps with the aid of
guides. The top roller applies the pressure and gently eases the tablet past the
hinge of foil. There is no tearing of the foil and the product is undamaged. The
recovered product is free from aluminum pieces. RECYCLE PACKAGING
Q. What about child-resistance?
A: Any pack which has to be specially manipulated before being opened can be
satisfactorily recovered using special machinery which first perforates the paper
backing and then gently eases out the product for full recovery.
Ernest Parker, SEPHA Products www.sepha.com (Stephen Mons, Kalish Inc.)
8
CENTRAL CANADA CHAPTER
MAY 2000
No.19
Security is more than just a firewall...
There seems to be no end in sight to random attacks by hackers who
gain pleasure by creating havoc for kicks. If you do not already have a
robust security system in place, you should urgently consider a system to
protect your assets from both outside and within.
The following is a list of questions that will help in defining your requirements that will have a large impact on implementing the appropriate solution
for your business. How secure is your enterprise? Can you assess security vulnerabilities and effectiveness of your corporate security policy? Is
your enterprise appropriately protected from unwanted outsiders and
hackers? Can you securely enable remote users, suppliers, partners and
customers to safely access your network via the Internet? Can you centrally manage and administer every user and resource across your organization?
I was recently at a seminar where the presenter effectively illustrated
the effects of an unfriendly intrusion on an e-Commerce business using
the analogy of thugs parking cars and abandoning them to block all access
to a Shopping Center’s parking lot. Needless to say it would severely limit
the amount of business transactions for the impacted period.
To be sure, there are many details to consider when talking about
establishing a secure corporate system.
I don’t mean to be paranoid, but you are responsible to help create the
"perfect solution". This article is intended to trigger an understanding that
network security is a more complex solution than a simple Firewall that
provides a secure operating environment for your business. I would ask
you to consider network security as a process rather than a product.
Mark Steiman, VP Business Development
www.3-SOFT.com
Toronto office: 905-502-3487
Ottawa office: 613-830-3484
Montreal office: 514-288-8919
Quebec City: 418-654-2412
Experience has shown that appropriate solutions are not easy to provide
without the client possessing a clear understanding and having established
a position on some essential points that are needed to successfully
design, implement and manage solutions.
There are some major issues and evaluations to be considered before
arriving at a solution. The most basic of which is to determine if your
company has a corporate security policy and to determine if it is relevant
to today’s computing environment. The answer is fairly complex as there
are several layers of policies that should be established at a granular level,
which makes it easier to enforce using technology. The policy areas
include the following; general security, access control, mission-critical systems, e-commerce security, e-mail use, unauthorized software and
Internet acceptable use. These policies are used to establish the guidelines of use and measurement in the selection and implementation of
security tools and controls.
This seems to be a task hated by many. The following
may help you when you are stuck for just the right phrase.
• His men would follow him anywhere, but only out
of morbid curiosity
• Works well when under constant supervision and
cornered like a rat in a trap
• He sets low personal standards and then fails to
achieve them
• He’s been working with glue too much
• When his IQ reaches 50 he should sell
• If you see two people talking and one looks bored,
he’s the other
• He brings lot of joy whenever he leaves the room
• This employee should go far, and soon, I hope
• This employee is depriving a village somewhere of
an idiot
Despite the best plans, most policies are prone to failure despite the
strongest enforcement if there is an absence of an excellent communications strategy to employees. This is an essential part of the solution.
Policies are unenforceable as they are not specific enough to govern the
behaviour of individuals under all circumstances.
The ideal solution will be much broader than a firewall as it should provide for authentication, authorization and access control within existing
databases. In addition, the solution must be scalable as your business and
corresponding network is sure to grow in the future. The security package
should ideally be integrated so that ease of use can reduce the costs associated in managing the solution.
SERVICING
CANADA & U.S.
I suppose I should be more optimistic and find some
complimentary quotes but it’s not as much fun.
Mike Coney
Serving the Pharmaceutical
and Biotech Industries
ISO 9002:
1994 REGISTERED
The Environmentally Friendly Chemical
Cleaning Service Company
•Passivation •Derouging •Sanitization •Descaling
180 Lesmill Rd., Studio 18
Toronto, Ontario M3B 2T5
DALPRO
INDUSTRIAL CLEANING OF AMERICA, INC.
Jay Levine
David Lauzon
339 LEASIDE AVENUE / STONEY CREEK, ONTARIO L8E 2N8
PHONE: (905) 662-2550 / FAX (905) 662-0117
9
Tel: (416) 447-1836
Fax: (416) 447-7825
[email protected]
MAY 2000
CENTRAL CANADA CHAPTER
No.19
World Pharmaceuticals
News - 23 may, 2000.
The merger, formally unveiled in London, will create the world's No. 1 drug
maker, to be called Glaxo SmithKline PLC. Based on pro forma 1998 results,
annual sales of the new company would total $24.9 billion, reflecting divested
businesses. The combined businesses would have 107,000 employees and
positions of global leadership in vaccines and in the treatment of diseases ranging from AIDS and asthma to migraine. The new company is expected to slash
about 10% of its combined work force over three years with cuts in middle
management and administration. Under the structure of the deal approved by
both boards, Glaxo shareholders will receive one share of a new company for
one Glaxo share. SmithKline Beecham shareholders will get 0.4552 Glaxo
share for each SmithKline share they own. Glaxo shareholders will control
58.75% of the new company, while SmithKline shareholders will hold
41.25%. The new group would be headquartered in London, but largely run
from a new operational base in the U.S., possibly New Jersey, the Londonbased Financial Times newspaper said. The group would have a 7.3% share of
the global pharmaceutical market.. Under the plan, the companies expect cost
savings of about 1.1 billion pounds ($1.76 billion) after three years, the
Financial Times reported. The merger is expected to take at least six months to
complete (Q3 2000). The planned merger still must be approved by the
Federal Trade Commission and the European Union.
The past 8 months have continued to see changes in the
pharmaceutical industry.
The industry has continued to consolidate, creating
several large companies.
The following is review and brief look at the last 8 months:
Pharmacia Corporation' Selected as Name for Company Created By
Merger of Monsanto and Pharmacia & Upjohn
Monsanto and Pharmacia & Upjohn entered into a definitive agreement to create a dynamic and powerful new competitor in the global pharmaceutical
industry. Pharmacia Corporation was selected as the name of the new company to be created through the merger of Monsanto and Pharmacia & Upjohn.
The combined company will have estimated 1999 sales of $17 billion with a
market capitalization of more than $50 billion. Under the terms of the mergerof-equals transaction, which has been unanimously approved by both boards
of directors, Pharmacia & Upjohn shareowners will receive 1.19 shares of the
combined enterprise for each share of Pharmacia & Upjohn they now hold.
Each Monsanto share outstanding prior to the combination will represent one
share in the combined company. The Searle, Upjohn and Pharmacia names
will be used to designate sales divisions in the new company in order to maximize the strong, existing customer awareness and relationships associated with
these businesses. The combined company will have an autonomous agricultural subsidiary, which will retain the name Monsanto. The agricultural business
has a leading global position in seeds, herbicides and biotechnology traits. In
conjunction with the creation of the new company, it is expected that up to
19.9 percent of the agricultural business will be offered in an Initial Public
Offering (IPO). The agricultural business will become a separate legal entity,
with a stand-alone board of directors and its own publicly-traded stock upon
completion of the intended IPO. The new company's corporate headquarters
will be located in Peapack, NJ, along with the pharmaceutical business. The
new company's agriculture business will be headquartered in St. Louis.
Teva Pharmaceutical Industries Ltd. Signs Definitive Agreement to
Acquire Novopharm Ltd.
Teva Pharmaceutical Industries Ltd, signed a definitive agreement to acquire
100% of Novopharm Ltd. from Dan Family Holdings Ltd. (the "Dan Family").
Upon the consummation of the transaction, the Dan Family will be entitled to
receive approximately 4.2 million Teva Ordinary Shares, representing approximately 6% of Teva's outstanding share capital (on a fully diluted basis). At
closing, a portion of the shares will be issued to the Dan Family in the form of
non-voting exchangeable shares of a Teva Canadian acquisition subsidiary.
These exchangeable shares will be exchangeable by the Dan Family at any
time, in whole or in part, into Teva Ordinary Shares at a one-to-one exchange
ratio. The balance of the share consideration will be allotted to the Dan Family
in the form of Teva Ordinary Shares. The closing of the transaction took place
on March 31, 1999. Novopharm is a privately held group of Canadian companies, and is the second largest generic company in Canada (with a market
share of about 20%). The Novopharm group also has a substantial presence
in the U.S. generic market as well as in Hungary and markets its products in
over 50 countries. The company's sales (the part being acquired by Teva) for
the first 9 months of 1999 reached US$297 million, of which approximately
47% were in Canada, 22% in the United States and 29% in Hungary.
Novopharm's primary business is the development, production and marketing
of generic prescription pharmaceuticals including sterile products, vitamins and
over-the-counter products. Novopharm has more than 10 production sites situated in Canada, the United States and Hungary. The headquarters and principal production sites are based in Toronto. Novopharm presently employs
approximately 2700 employees, of which approximately 55% are in Canada,
5% in the United States and 40% in Hungary.
Pfizer and Warner-Lambert Agree to $90 Billion Merger Creating the
World's Fastest-Growing Major Pharmaceutical Company
Pfizer Inc and Warner-Lambert Company announce they have entered into a
definitive merger agreement to create the world's fastest-growing major pharmaceutical company. Under terms of the merger agreement, Pfizer will
exchange 2.75 shares of Pfizer common stock for each outstanding share of
Warner-Lambert stock in a tax-free transaction valued at $98.31 per WarnerLambert share. The combined company will have annual revenues of approximately $28 billion, including $21 billion in prescription pharmaceutical sales,
and will have a market capitalization in excess of $230 billion. Compounded
annual revenue and earnings growth are expected to be 13 percent and 25
percent, respectively, through 2002. Upon completion, Pfizer's shareholders
will own approximately 61% of the new company on a fully diluted basis, and
Warner-Lambert shareholders will own 39%. The merger agreement between
Warner-Lambert and American Home Products has been terminated and the
cross-options have been rescinded without consideration. Warner-Lambert is
paying AHP a $1.8 billion break-up fee. Corporate headquarters of the company will remain in New York. The Warner-Lambert Consumer Health Care
Division, along with the other consumer businesses and selected additional
functions, will be located at Warner-Lambert's offices in Morris Plains, N.J. The
worldwide and U.S. pharmaceutical division headquarters will be in New York
with operational support functions in both New York and Morris Plains.
Andrx Acquires Valmed Pharmaceutical, Inc.
ANDRX CORPORATION announced that it closed on the acquisition of Valmed
Pharmaceutical, Inc., a privately owned distributor of generic pharmaceuticals
based in Grand Island, New York. Andrx acquired Valmed for approximately
$14,800,000 in cash. Valmed recorded distribution revenues of approximately
$40 million for the year ended December 31, 1999 and was profitable. As
previously announced, the acquisition is expected to have a modest accretive
effect on Andrx' future financial results.
Glaxo Wellcome PLC and SmithKline Beecham PLC Unveil a
"Merger-of-equals"
British pharmaceutical giant Glaxo Wellcome PLC and Anglo-American drug
maker SmithKline Beecham PLC unveiled a "merger-of-equals," under which
Glaxo will acquire SmithKline in a 46.3 billion ($75.7 billion) stock swap.
AstraZeneca sees potential EU fine at 80-160 mln skr; not 50 bln
AstraZeneca PLC said its exposure to an EU fine relating to the company's
patent extension for Losec would under EU rules be 10 pct of the drugs sales
10
MAY 2000
CENTRAL CANADA CHAPTER
No.19
News News News
in Germany, not 10 pct of its global sales, and as such could be as low as 80
mln skr. Mikael Widell, press officer at AstraZeneca said sales of Losec in
Germany are currently running at around 800 mln skr per year, or around 1.5
pct of its total. Widell said that the company expected any fine to be for around
one or two years, or 80 to 160 mln skr. The maximum period would be five
years or around 400 mln skr, Widell said. "We would typically expect a fine to
relate to 1 or 2 years, although theoretically it could go to five, as that is the
length of time that we had an extension and thus would be liable for, were the
case to go against us," said Widell. Earlier reports indicated that the company
faced a potential fine of 50 bln skr. AstraZeneca said the documents submitted
to the EU relate to a long running battle with German generic company,
Ratiopharm which claimed the company was inelligible for a patent extension
on Losec in Germany. Under EU patent rules, companies are not entitled to a
patent extension or Supplementary Patent Certificate (SPC) for drugs launched
after 1988 in Germany and Luxembourg, or 1985 in other states. The case
was brought before the EU in December 1999. AstraZeneca press officer
Mikael Widell confirmed that the EU has made enquiries relating to its case
documentation, but declined to comment on reports that the commission
authorities have raided its offices.
Can$1.8 billion of investment by the pharmaceutical industry. The association
also said that the measure would cost the government up to Can$20 million in
lost taxes. There will be further reform of the drug insurance plan, Ms Marois
said. Patient access to medicines needs to be improved and drug approval
times reduced, and there will be a review of the criteria under which pharmaceuticals are listed for reimbursement. A multiparty committee will also be set
up to study the feasibility of streamlining drug insurance coverage.
Canadian Federal Government Appeals WTO Ruling
Government ministers John Manley, Pierre Pettigrew and Allan Rock announce
that the Government of Canada is appealing a WTO U.S. ruling that stipulates
Canada must extend its patents. Abiding by this ruling would delay the introduction of generic drugs as alternatives to approximately 25 brand name drugs
currently under Canadian patent protection. In its ruling, the WTO backed
Washington, which had complained that Ottawa had been wrong to allow
patents to be given a 17-year protection period rather than 20 years. The decision requires Canada to provide 20 years of patent protection to more than
160,000 patented products.
WTO upholds Canada's "early working" rule
The World Trade Organisation ruled against big claims brought by the European
Union in a case brought against Canada's patent regime. The EU had sought to
abolish Canadian provisions that allow generic drug manufacturers to begin
research and product-testing on copies of brand-name drugs before the patent
has expired. That allows the cheaper copies to hit the market as soon as the
patent expires, saving three to four years in development time. The EU, which
has about a 45 per cent share of the Canadian drug market, said the rules
were costing its industry several hundred million dollars a year. The WTO did
side with the EU in ruling that generic drug makers could not begin manufacturing and stockpiling the copied drugs before patents expired.
Quebec retains 15-year rule
The Quebec government will retain its 15-year rule under which doctors and
patients are allowed to use branded products as a first option for 15 years after
they first appear on the government's reimbursement list. The decision follows
a review of the province's drug insurance plan, which considered ways of
reducing the Can$142 million deficit the plan is facing this year. Health
Minister Pauline Marois said the proposal to replace the 15-year rule with a
"best available price" policy would have brought only Can$22 million in savings. Instead, the government is to increase drug insurance premiums and
examine further reform of the system. The review had attracted heavy lobbying by the Canadian research-based pharmaceutical industry association, Rx&D,
which claimed that adoption of a best available price policy could jeopardise
George de Carvalho, Genpharm Inc.
Le génie pharmaceutique : une nouvelle approche
résumé de la conférence
Le 17 mars dernier, deux conférenciers sont venus rencontrés les étudiants de l'École Polytechnique de Montréal afin de leur donner une idée du génie
pharmaceutique et du rôle de l'ingénieur dans ce milieu en forte croissance.
En premier lieu, M. André-Pierre Ghys, ingénieur chez Pellemon, nous a donné un bref historique de l'industrie pharmaceutique incluant la naissance de
la première industrie moderne en 1897, Bayer qui a su inventé la production de l'aspirine en grande quantité, ainsi que la mise en place des Bonnes
Pratiques de Fabrication (BPF) en 1976 et des lignes directrices de l'ISPE en 1998. Le domaine des biotechnologies est un secteur très spécialisé qui renferme à lui seul 1 300 entreprises mondiales. À l'heure actuelle, un gramme d'une hormone de croissance synthétique vaut 20 000 $, comparativement à
un gramme d'or qui vaut 10 $, ce qui démontre bien l'importance de l'implantation des biotechnologies dans l'économie même si la recherche peut exiger
un bon nombre d'années avant la mise au point d'une biotechnologie.
En second lieu, M. Markc Cupryk, ingénieur chez Merck Frosst Canada ltée, nous a décrit la situation actuelle du secteur des biotechnologies au Canada et
nous a tracé un bref portrait de l'ingénieur en milieu pharmaceutique. Au Canada, Montréal est devenu la capitale des biotechnologies; les industries oeuvrant dans ce domaine cherchent constamment à se spécialiser et à innover. La formation universitaire est de plus en plus importante dans ce milieu et les
possibilités d'emploi sont incroyables quelque soient les aspirations professionnelles (possibilités de s'ouvrir au monde extérieur par des voyages, sécurité
d'emploi, salaire important, etc.). De plus, M. Cupryck a mentionné que la FDA est, à chaque année, plus exigeante d'où l'importance de la validation dans
les industries pharmaceutique. Enfin, l'ingénieur en milieu pharmaceutique devra aimer le travail en équipe, être un bon communicateur et avoir de l'habilité en gestion de projets. Bref, ce domaine offre beaucoup de diversité et de grandes opportunités mais la compétition entre les industries est très forte.
En somme, cette conférence a permis aux étudiants de l'École Polytechnique d'en connaître d'avantage sur le milieu pharmaceutique et sur les opportunités de travailler dans un tel milieu. Nous remercions M. André-Pierre Ghys et M. Markc Cupryk d'avoir partagé avec nous leur expérience professionnelle.
Annie Sénéchal, Directrice des activités
11
MAY 2000
CENTRAL CANADA CHAPTER
Some More News
News
No.19
News News
company with the broadest range of products. The new name sees the end of
the "Connaught" name whose company history dates back 85 years - to the
beginning of vaccine production in Canada. Aventis Pasteur manufactures or
distributes over 30 vaccines and immunotherapeutic products. Recent product
innovations include the Pentacel vaccine which guards against the five most
common childhood diseases in one single injection. With 1,000 employees
working at its fully integrated site in Toronto, Ontario, Aventis Pasteur is a major
R&D site for the global company. Current research focuses on possible vaccines against childhood ear infections, respiratory infections and therapeutic
vaccines to treat certain cancers. The company, in Canada, will continue to be
led by President, J. Mark Lievonen.
Paladin Labs inc. to aquire the Canadian License to a line of
Dermatology Products from Baker Norton Pharmaceuticals, inc.
Paladin Labs Inc. ("Paladin") (CDNX: PLB) announced that it has acquired the
exclusive Canadian license from Baker Norton Pharmaceuticals, Inc., a subsidiary of IVAX Corporation (AMEX:IVX), to a line of established dermatology
products. The products include X-SEB, P&S, Ultra Mide and Acquaderm lotions
and shampoos, with estimated sales in Canada of approximately $400,000.
Shire And Roberts Merger Completed
Shire Pharmaceuticals Group PLC (Nasdaq: SHPGY; LSE: SHP.L) announces
the completion of the merger with Roberts Pharmaceutical Corporation
(Roberts) (Amex: RPC) following shareholder approval from both companies.
Shire Pharmaceuticals Group PLC (Shire), following the merger, has a market
capitalisation of 1,505 million Pounds Sterling ($2,423 million). The listing of
Roberts' common stock on the American Stock Exchange has been cancelled.
The 100,767,482 new Shire ordinary shares are expected to be admitted to
the Official List of the London Stock Exchange and commence trading on
London Stock Exchange and Nasdaq. In accordance with the predefined cap
and collar ratio for the share exchange, Roberts shareholders' will receive exactly 3.1280 new Shire ordinary shares for each share of Roberts stock they hold
or approximately 1.0427 Shire ADSs, depending upon their stated preference.
This ratio was determined based on the average closing price of Shire's ADSs
for the 15 consecutive trading days ending the third trading day prior to closing,
which was $33.43. The acquisition by Shire of Roberts outstanding shares in
this share-for- share exchange resulted in a total transaction equity value of
620 million Pounds ($998 million).
Synapse receives patent for Alzheimer disease diagnostic
Synapse Technologies Inc. has announced that the US Patent Office has issued
US patent 5,981,194 for p97 Diagnostic Assay, a diagnostic test that will assist
physicians in diagnosing Alzheimer's Disease. The company holds the exclusive
rights to develop and market the test worldwide, under license from the
University of British Columbia In making the announcement , Dr. Jean-Paul StPierre, President & CEO said, "Currently, there is no single diagnostic factor
which identifies Alzheimer's Disease in patients. However, this test will provide
physicians with an early diagnosis and help to improve patient care by permitting timely treatment of this devastating disease." The Synapse test targets a
particular protein (p97) that is found in higher concentrations in people who
suffer from Alzheimer's Disease. By examining p97 levels, a diagnosis can be
made, since higher concentrations of the protein are predictive of the disease.
In addition, this approach can be used in monitoring the disease's progress.
The company is continuing to develop the test for patient use and anticipates it
will be available to the market in the year 2000. Based in Vancouver, Synapse
Technologies Inc. is a biotechnology company specialising in the research and
development of new technologies for drug delivery to the brain and the identification of new drug targets in neurodegenerative disease. The company, whose
experience with p97 is the foundation for its investigations, works closely with
prominent researchers and clinicians from the University of British Columbia
Biopure receives clearance to expand Hemopure trial into Canada
Biopure® Corp. (Nasdaq: BPUR) has received approval from Health Canada's
Bureau of Biologics and Radiopharmaceuticals to expand its pivotal Phase III
clinical trial on its oxygen therapeutic, Hemopure(R) [hemoglobin glutamer 250 (bovine)] into Canada. The trial is evaluating Hemopure as a room temperature stable, universally compatible alternative to red blood cell transfusion
in orthopedic surgery. As of October 1999, Biopure's Phase III clinical trial had
enrolled more than half of the required 640 patients and had expanded to
more than 30 clinical trial sites in the United States, Europe and South Africa.
Patient enrolment at participating clinical sites in Canada is expected to begin in
January. The company plans to complete this trial and file a marketing application in the United States during 2000, followed by applications in Canada and
the European Union. Biopure's pivotal trial is designed to gauge the safety and
effectiveness of Hemopure when compared to allogeneic red blood cells in
patients undergoing general elective orthopedic surgery. Biopure's oxygen therapeutics consist of bovine hemoglobin that has been ultrapurified, chemically
cross-linked for stability and formulated in a balanced salt solution similar to
Ringer's lactate. On a gram-for-gram basis, this cross-linked hemoglobin carries
the same amount of oxygen as the hemoglobin in red blood cells. These polymerized hemoglobin molecules have no cell membrane, are much smaller
than red blood cells, circulate in plasma (the fluid part of blood) when administered, and have a lower viscosity (resistance to flow) and more readily release
oxygen to tissues than blood. Consequently, they have been shown to carry
oxygen through constricted or partially blocked blood vessels to areas of the
body that are difficult for larger red blood cells to reach.
Axcan licenses proton-pump inhibitor
Montreal - Axcan Pharma Inc. has reached an agreement with Il Yang Pharma
Co. Ltd. of Korea granting Axcan an option to license (except for Korea and
China) IY-81149, a new proton-pump inhibitor. Il-Yang has been granted an
option to Axcan's HelecideT, a single capsule bismuth-based triple therapy for
Helicobacter pylori eradication, for the territories of Korea and China. Protonpump inhibitors are one of the most prescribed classes of drugs in the world
with estimated sales exceeding US$5 billion. IY-81149 is a new molecule
belonging to this class of drugs and is currently in Phase II development in
North America. Proton-pump inhibitors are used in the treatment of conditions
where a reduction of gastric acid secretion is required, such as gastroduodenal
ulcers, gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome and
Helicobacter pylori infection.
BCS Inc.
BCS INC. is pleased to announce that our move into our new 10,000 sq.ft.
facility in Oakville, Ontario is now complete. The larger facility has enabled us to
double our service capability with our overhead crane capacity increasing to 3
tonne. Our passivating line has been increased with an additional 5 dip tanks
being added. The clean room assembly and packaging department is almost
complete. Our Boroscoping service is running full tilt and we are looking at
adding a 0.6 mm capable scope to enable us to view extreemly small bore
tubing. We would be more than happy to have members of the ISPE visit our
facility. PLEASE NOTE our new address is 735 Weller Court, Oakville, Ontario,
L6K 3S9 Tel:(905)815-8975, Fax:(905)338-7791, E-mail: [email protected],
Web Site: www.corrosion-protection.com
Aventis becomes major international life sciences company
As a result of the merger between Hoechst AG and Rhone-Poulenc SA., a new
global force in life sciences has been created. Named Aventis, in Canada, five
distinct groups will represent the new company: Aventis Pharma, Aventis
Pasteur, Aventis Behring, Aventis CropScience and Aventis Animal Nutrition. In
total, the new company will employ nearly 2000 people in Canada and will
have total revenues in 1999 of over $750 million. Aventis Pasteur Limited
(formerly Pasteur Merieux Connaught Canada) is Canada's largest vaccine
Perry Elliott
12
MAY 2000
CENTRAL CANADA CHAPTER
No.19
Pharmaceutical
Engineering
in the
Department of chemical engineering
What is Pharmaceutical Engineering ?
"Pharmaceutical engineering", as defined in the industry, refers to a
branch of process engineering dedicated to "clean processes". Such
processes are found in the pharmaceutical and other related industries,
such as bulk drugs, fine chemicals, biochemistry and cosmetics industries.
Process engineers responsible for developing, designing and implementing
these "clean processes" were traditionally issued of chemical engineering
programmes. The rapid growth observed in the pharmaceutical sector in
particular, during the last few years, has certainly contributed to the
increasing demand for engineers with very specific abilities, which include,
in addition to the basic process engineering skills:
2. 4.570 : Process Validation (3 credits : compulsory)
This course deals with the norms, regulations and practices related to the
"clean process" industry. Covered topics include: norms and regulations
(e.g. cGMP, FDA approval) and validation procedures for systems, processes and equipment.
3. 4.550 : Advanced Separation Processes (3 credits : optional)
Course on separation processes related to the "clean process" industry for
the purification and recovery of high value products.
4. 4.504 : Bio-Chemical Engineering (3 credits : optional)
Course on transport phenomena applied to bioreactor engineering.
Covered topics include: equipment selection for bio-production, sterilisation procedures and bio-reaction kinetics.
• knowledge of the norms and regulations applicable to
the various "clean process" industries;
• training in validation and assay procedures;
• training in quality control, safety and environmental
protection;
• knowledge of various unit operations associated with
"clean processes"
5. IND3104 : Industrial Automation (3 credits : optional)
Course on methods for process automation.
6. ST-403 : Industrial Internship (3 credits : compulsory as part of the
COOP regime)
As a result of such training, the role of the pharmaceutical engineer
would be to "develop and operate manufacturing processes that meet the
requirements of safety, quality, consistency, cost operability and environmental protection, making it possible to market products of significant
value" (Rosas and Paul, Chemical Engineering Progress, December 1990).
All students registered in the pharmaceutical engineering orientation must
be in the COOP regime. They must spend at least one 8-month and one
4-month internships in the pharmaceutical or other "clean process" industry.
Professors of Pharmaceutical Engineering
In the Department of Chemical Engineering at Ecole Polytechnique, three
professors are involved in R&D activities directly related to the field of
Pharmaceutical Engineering:
• Mario Jolicoeur, P.Eng., Ph.D. Assistant professor. Specialist in metabolic
Why a speciality in pharmaceutical engineering at Ecole
Polytechnique ?
Two main reasons are responsible for developing a pharmaceutical
engineering programme at Ecole Polytechnique:
and bio-process engineering.
1. The province of Quebec, and the Montreal region in particular, is
being recognised as a major pharmaceutical centre. The
Pharmaceutical Manufacturers Association of Canada (PMAC) recently reported that "Over twenty member companies of the PMAC are
located in Quebec. In addition, twelve other PMAC member companies, have business offices in Quebec. Together, they make a sizeable contribution to the economic well-being of the province, making
Quebec a major centre for pharmaceutical R&D in Canada" ;
• Robert Legros, P. Eng., Ph.D., Full professor. His research activities include:
separation process for purification and recovery of bio-products, downstream
processing and powder technology. Responsible of the Pharmaceutical
Engineering speciality.
• Michael Buschmann, P.Eng., Ph.D., Associate professor. Specialist in tissue
and bio-material engineering, drug delivery and human tissue reconstruction
(cartilage, skin, etc.).
Contact:
Dr. Mario Jolicoeur, Faculty advisor of the ISPE Student chapter
2. The present Chemical Engineering programme at Ecole
Polytechnique offers a solid Process Engineering training on which to
build the pharmaceutical engineering specialisation.
at École Polytechnique
Phone: 514-340-4711, ext. 4525
Fax: 514-340-4159
[email protected]
The Pharmaceutical Engineering specialisation for chemical
engineers at École Polytechnique
The objective of the proposed chemical engineering orientation is to
supply engineers to the "clean process" industrial job market. In order to
achieve this objective, the department of Chemical Engineering at the
École Polytechnique of Montréal, has created a 12 credits orientation in
Pharmaceutical Engineering. The courses that are part of this orientation
are presented below.
NICOLAIDIS
FUKUSHIMA
ORTON
EMMIAN
The Pharmaceutical Engineering Orientation
(Total of 12 credits including 9 compulsory and 3 optional)
1. PHM6038 : Industrial Pharmaceutical Forms (3 credits : compulsory)
The objective of this course is to introduce the students to the different
steps leading to the manufacturing of drugs in various forms: different
aspects of galenics, process and technology are presented. The University
of Montreal's Faculty of Pharmacy offers this course, as part of their DESS
in Drug Development.
Specialists in design
of pharmaceutical,
biotechnology and
life science facilities
Architects
1255, University, Suite 700, Montréal, Québec, H3B 3W1
Tel.:(514) 397-2616, Fax (514) 861-5242, E-mail: [email protected]
13
MAY 2000
CENTRAL CANADA CHAPTER
No.19
Third Party Logistics
To some third party logistics may be a fate worse than death, but for
the right reasons can be utopia every day of the week. There are many
companies dealing in the service of third party logistics and there are a
myriad more that have never ever considered the option or have a knee
jerk reaction to the idea.
Third party logistics services have been around since the dawn of commerce. Every time you request another company to deliver materials, you
are using third party logistics. The formalisation of the term "Third Party
Logistics", seems to have arced out of the fires of "Outsourcing" and in
turn fuelled by the "Downsizing Syndrome" followed hard on the heels of
"Developing Core Competencies".
Focusing on your core business is the name of the game when you
consider third party logistics.
Is any one out there doing their own inner city courier deliveries? Is
there any one out there servicing their fax and copy machines? Is there
anyone flying his or her own cargo planes to Europe? I doubt it, unless it
is your core business!
You are doing your own production, your own quality control, your own
investigations of new products for new markets and managing your own
sales representatives. I am also sure you could find a third party to do
some of those tasks.
The key to a successful relationship with a third party logistician is a
clearly defined role for the third party and from your perspective a clearly
defined result and expectation of the third parties’ roles. For example, the
third party courier role is clearly defined. The expectation of an outcome is
not negotiable, the deliveries take place, and the service expectation is fulfilled. If delivery does take place you will promptly heat up the telephone
wires to the offending Courier Company.
The next level of third party logistics after the clearly defined courier
option, is the freight carrier. Who needs to own a fleet of 52-foot trailers,
along with the labour issues, truck maintenance issues, licensing
headaches and low utilisation of deck space? I do not and, I am sure, you
do not need it. We have other fish to fry and core competencies to develop!
The next level of third party logistics is warehousing of materials.
Warehousing is relatively cheap and set-up costs for new facilities are not
excessive. Do you need to own the fleet of forklifts, the gas and hydro
bills, the labour issues, the canteen, the facility maintenance, the additional
Thinking of merging?
space for expansions? I don’t, or not all of it anyway. You may need to
warehouse your own raw materials but you could get creative with your
suppliers and let them do it for you. You may need to have warehouses
for semi finished products, work in process storage and some holding
areas for the finished product. For your finished inventory do you need to
own thousands of square feet, racking to the rafters and all that goes with
it, I don’t, do you?
The next level of third party logistics is the labour-intense pick, pack, and
ship operations. Do you need to control this operation? Are there intrinsic
value adding operations in this process that only YOU can do?
Alternatively, is it the common garden-variety picking slip instruction, packing instruction, and shipping instruction that any Joe Bloggs outfit could follow? I wonder? Well for me in the high-end level of pharmaceutical quality
requirements I can find more than a few speciality third party logisticians
that can do the job for me.
The next levels of third party logistics are the outsourcing of the order
taking, managing customer complaints, customer returns and even the
outsourcing of the sales force. It may be way beyond many companies’
cut-off point but for some companies, the opportunities may be attractive.
Do you lose control of your business and the direction of your business
by using third party logistics? Emphatically no, in fact you may get better
control as you focus on the value adding operations of the logistics chain
that makes you successful.
Does third party logistics cost more than doing it yourself? Every situation is different but a cost study may typically show a warehousing operation could be done in house for 20% less than the third party. However,
10% of the difference can be accounted for by profit motives and the
remaining 10% to errors and assumptions. The intangibles benefits of
focusing on your business, paying on a service as required basis, no worries about expansions and guaranteed levels of service far out weigh the
"astronomical" 10% profit you are forking out or the 10% uncertainty
assumption factor.
You’ll not lose control in fact you will still specify the service levels, quality requirements and be able to negotiate every aspect of the costs of a
third party logistic service. Do it or live with your logistics headaches?
Richard Kropman, P. Eng. Genpharm Inc.
[email protected]
The challenges that can make or break the deal
"When putting a merger together, companies often tend to rush through the
process without considering the impact that the transaction might have down the
road. Organizations are combined at 'breakneck' speed. The potential for error is
high and the cost of a minor misstep can be enormous," says Kerrie
MacPherson, Managing Partner of Ernst & Young's Mergers & Acquisitions Due
Diligence Practice.
Buyers of businesses in foreign jurisdictions face even greater challenges due to
the cultural (and legal) differences that exist in other countries. There are many
things to consider when merging two companies together. In addition to considering whether they have centralized or decentralized management systems, purchasers must assess different accounting or tax practices, different legal environments and potentially very different human resources practices. "It's all these little
things that can make or break a deal," says MacPherson.
So what are the factors for success during these uncertain times?
Companies need to address the following in order for a merger to succeed:
What are some of the challenges companies encounter?
•
•
•
•
•
•
•
•
Competing agendas and perspectives
Internal and external time pressures
Limited time to consider implementation efforts
Lack of experience in acquisitions, analysis and negotiation
Failing to maintain customer focus - Loss of control
Organizational confusion and division
Flight of talent, knowledge and/or capital
Inflexibility - Lack of leadership.
•
•
•
•
Leadership
• Clear Vision and Target • Communication
Retention of Key Talent • Cultural Integration
• Customer Focus
Performance Tracking • Systems Integration
• Change Management
Implementation
"If a merger or acquisition is done properly, a company can realize economies of
scope and scale. The new entity can capitalize on each party's knowledge, capabilities, markets and customer relationships. But if it's not done properly, the time
and money that go into the transaction can really be wasted. Bringing in the right
team of advisers to assist from thought to finish is an important element of success," says MacPherson.
Perry Elliott
"Mergers can be overwhelming for both organizations and their employees. And
ultimately, people need time to understand what this means for them.
Organizations need to devote more effort to both their financial and communications models and factor in all these things before moving ahead with the merger," says MacPherson.
14
MAY 2000
CENTRAL CANADA CHAPTER
No.19
INTERNET:
Find what you’re looking for Faster!
If the information exists, you can find it on the Internet … but where? And how do you find it without struggling with Boolean operators or typing the same request seven times in different search tools? Following are a few simple tips and tricks that will speed up your search:
1) USE THE RIGHT BROWSER :
If you are looking for something simple, start with Yahoo. Browsers such
as Excite, Lycos or Hotbot are more suitable for in-depth research. If you
still don’t get the results you want, use the Meta-browsers. These search
tools will distribute your request to several browsers simultaneously, which
multiplies your chances of finding what you are looking for. The bestknown Meta-browsers are:
5) SET LIMITS:
Most search tools allow you to use META-words before your keyword,
which limits your search to titles, for example, or particular areas. Thus, if
you are in AltaVista and type TITLE:ROGER, you will receive just Web pages
whose title alone contains the word Roger.
6) FIND HIDDEN INFORMATION:
The conventional search tools do not have access to all the information on
the Web. The www.powerize.com site will find information hidden in
either subscription or free sites that cannot be accessed by search tools.
You can search for articles, financial reports or analyses from more than
8,000 sources. Most of the documents may cost a few dollars, but
Powerize provides a synopsis, so that you know what you are buying.
- Dogpile ( www.dogpile.com )
- Mamma ( www.mamma.com )
- Metacrawler ( www.go2net.com )
- Profusion ( www.profusion.com )
- Savvysearch ( www.savvysearch.com )
2) OPTIMIZE INTERNET EXPLORER:
7) SOME TRICKS:
From the www.hotbot.com site, you can access the HotBot's SuperSearch
site by clicking on More Search Options. Now you can specify the language, words that must be included/excluded, and even the type of files
you are looking for (are you looking for .dll files for Windows?).
IE 4.0: Download PowerToys
IE 5.0 : Download Web Accessories.
These two additions will provide you with instant access to several
browsers.
3) FIND WHAT YOU ARE LOOKING FOR:
To find a person (Win 98): Click on Start - Search - Persons and use the
scrolling list to select the source. If you are already on the Net, go immediately to the www.infospace.com site.
To find a company: Start by trying "www.nameofcompany.com". If you
are lucky, you will access the right site. If not, try www.comfind.com or
Happy hunting!
Jean-Luc Lavoie, 3-Soft.com
www.3-SOFT.com
www.iatlas.com
Need images, clips, music?
Do you need a photo of the mating dance of the rare African white rhinoceros, as well as a sound clip of its call? Try these sites:
- www.scour.net
- www.arribavista.com
- www.mp3meta.com
- mp3.lycos.com
4) NARROW DOWN YOUR SEARCH:
You are doing a search with single words but your browser makes
152,325 contacts. Yikes! … You better narrow down your search. Use the
+, - and " signs. The + sign before a work means that this work MUST
appear in the Web page; the - sign excludes it. Place your search phrases
in quotation marks if you want the browser to find this exact phrase.
15
Toronto office: 905-502-3487
Montreal office: 514-288-8919
Ottawa office: 613-830-3484
Quebec City: 418-654-2412
CENTRAL CANADA CHAPTER
MAY 2000
Presented by Robert Beaumont, April 21st in Toronto and
April 22nd in Montreal
This presentation was excellent and generated lots of
interesting questions from the audience.
Robert gave us a well-organized and understandable
introduction to legal and contractual issues that we need to
consider when making a major equipment purchase.
The areas covered included Specification of customer
needs; Tendering; Negotiating a contract and Testing and
accepting the equipment.
I found there were so many interesting points that I cannot
cover them all in this review. It really was a case of getting
your appetite wetted to study the subject more thoroughly.
Some of the points I found of most interest included:
Fairness over errors in tendering benefits both parties.
Bonus for early completion is very motivating to a supplier
but seldom offered.
Use milestones throughout the project phases rather than
relying on the final delivery date.
Avoid lengthy contractual requirements in tender packages,
negotiate a contract with the successful bidder.
Copyright on design and drawings.
Use of fair and reasonable approach to partnering between
supplier and customer.
The whole subject was made more interesting and relevant
by references to actual case law.
The presentation in Toronto was very well attended. This
may in part be due to word getting around about the excellent facilities provided to our Chapter by Glaxo Wellcome
for which I offer very sincere thanks from all who attended.
Be sure to attend the next breakfast meeting, there is
always something new to be learnt at every meeting and it
is an excellent way to meet other members.
No.19
ChapteProgram
r’s to november 22, 2000
Jun 23/00
Board Meeting
Toronto
Jun 23/00
Golf Tournament
•Richmond Hill Golf and Country Club
Toronto
Sep 20/00
Board Meeting
Montreal
Sep 21/00
AGM
Montreal
Oct 24-25/00
Breakfast Workshop:
•Data Envelopment Analysis
TO & Mt’l
Nov 15/00
Board Meeting
Toronto
Nov 21-22/00
Breakfast Workshop:
•Electrical Safety Code
TO & Mt’l
We now accept Visa and MasterCard as forms of payment
for all Chapter Events
Mike Coney
MONTREAL: TELEPHONE (514) 636-0032
BIO
CLEAN
SERVICES INC.
FAX (514) 636-8429
TORONTO: TELEPHONE (416) 844-2062
FAX (416) 844-0023
PURIFED WATER SPECIALISTS TO THE INDUSTRY
735 Weller Court
Oakville, Ontario
L6K 3S9
Tel. (905) 815-8975
Fax. (905) 338-7791
E-Mail: [email protected]
UF-RO-DO-CDI-FILTRATION
Industrial Chemical Cleaning
505-14 IROQUOIS SHORE ROAD
OAKVILLE, ONTARIO
L6H 2R3
PHARMACEUTICAL
CONSULTANTS
85 LINDSAY AVENUE
DORVAL, QUEBEC
H9P 2S6
Passivation • Descaling • Derouging • Degreasing • Boroscoping
HealthStar Limited
253 Summerlea Road, Unit 14
Brampton, Ontario
Canada, L6T 5A8
8000, Decarie Blvd
3rd floor
Montreal, Quebec (H4P 2S4)
Telephone: (514) 735-5651
Fax: (514) 737-7988
Equip Your Future...
• Packaging Machinery
• Tablet Presses/Capsule
Fillers
• Liquid & Powder Filling
Engineering • Construction • V a l i d a t i o n
R&D Facilities
Pilot Plants
Production Plants:
• Stoppering & Capping
• Granulation/Blending
Solids
Liquids
Injectables
• Autoclaves/Sterilization/
Freeze Dryers
16
• Machine Rebuilding
Services
• Equipment Referrals &
Search Service
• Equipment Liquidation
Services
• Equipment Purchase
• Tablet Dedusters &
Capsule Polishers
Perry F. Elliot
Vice President
Tel: 905-791-7735
Fax: 905-791-7736
Mobile: 416-460-7498
e-mail: [email protected]
http://www.healthstaronline.com